The involvement of nitric oxide in the analgesic effects of ketamine
Abstract
We investigated the contribution of NO-cyclic GMP (cGMP) pathway to the antinociceptive effects of ketamine in mice by using the nitric oxide synthase inhibitor nitro(g)-L-arginine methyl ester (L-NAME). Intraperitoneal (i.p.) (1 5 or 10 mg/kg) or intrathecal (i.th.) (10 30 or 60 mug/mouse) administration of ketamine produced dose-dependent antinociceptive effects in the acetic acid-induced writhing and formalin tests but not in the tail-flick nor in hot-plate tests. pretreatment of mice with L-NAME (10 mg/kg i.p.) which produced no antinociception on its own significantly inhibited the antinociceptive effect of ketamine (1 5 or 10 mg/kg i.p.). However L-NAME (30 mug/mouse) was given intrathecally it neither modified the antinociceptive effect of i.th. ketamine (10 3 0 or 60 mug/mouse) nor did it produce an antinociceptive effect alone. These data suggest that the activation of the NO-cGMP pathway probably at the supraspinal level but not spinal level contributes to the antinociceptive effects of ketamine. (C) 2002 Published by Elsevier Science Inc.
Source
Life SciencesIssue
7Volume
71Pages
841-853Collections
- Araştırma Çıktıları / PubMed [187]
- Araştırma Çıktıları / Scopus [1345]
- Araştırma Çıktıları / WOS [1335]
Keywords
KetamineNitric oxide
Analgesia
NMDA receptors
Anaesthetics
L-N-G nitro arginine methylester (L-NAME)
Formalin
Writhing
Pain
Dissociative anesthesia